Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Laurus Investment Counsel Inc.

Laurus Investment Counsel Inc. grew its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 10.4% during the 4th quarter, HoldingsChannel reports. The firm owned 79,150 shares of the medical research company’s stock after buying an additional 7,435 shares during the quarter. Charles River Laboratories International accounts for about 7.5% of Laurus Investment Counsel Inc.’s investment portfolio, making the stock its 5th biggest holding. Laurus Investment Counsel Inc.’s holdings in Charles River Laboratories International were worth $14,611,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. Empirical Finance LLC boosted its stake in shares of Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after acquiring an additional 53 shares during the last quarter. OLD National Bancorp IN increased its position in shares of Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after acquiring an additional 59 shares during the last quarter. Fiduciary Financial Group LLC boosted its position in shares of Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after buying an additional 63 shares during the period. Pinnacle Bancorp Inc. lifted its position in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Finally, M&T Bank Corp raised its stake in shares of Charles River Laboratories International by 3.4% in the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock valued at $394,000 after acquiring an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the subject of several recent analyst reports. UBS Group reaffirmed a “neutral” rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. The Goldman Sachs Group dropped their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target for the company. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $204.38.

Charles River Laboratories International Stock Down 0.4 %

CRL opened at $164.88 on Friday. Charles River Laboratories International, Inc. has a one year low of $159.65 and a one year high of $275.00. The company has a market cap of $8.43 billion, a price-to-earnings ratio of 20.64, a PEG ratio of 6.13 and a beta of 1.38. The business’s fifty day moving average is $184.15 and its two-hundred day moving average is $195.67. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.72 EPS. Analysts anticipate that Charles River Laboratories International, Inc. will post 10.17 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).